Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human clinical study of PH-762 in adoptive cell therapy with tumor infiltrating lymphocytes in patients with metastatic melanoma or squamous cell carcinoma of the head and neck (SSCHN)

Next Previous
Search
Trial Profile

A first-in-human clinical study of PH-762 in adoptive cell therapy with tumor infiltrating lymphocytes in patients with metastatic melanoma or squamous cell carcinoma of the head and neck (SSCHN)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PH 762 TME (Primary) ; PH-762-ACT (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 16 May 2023 According to a Phio Pharmaceuticals media release, the company plans to initiate this study in the second half of 2023.
    • 16 May 2023 According to a Phio Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to proceed with this study.
    • 21 Dec 2022 According to a Phio Pharmaceuticals media release, the company expects to file an IND in the US in the first half of 2023 for the trial. Phio expects to commence a US Phase 1b clinical trial early in the 2nd half of 2023. The initial US trial is expected to focus on the treatment of cutaneous squamous cell carcinoma (cSCC) and other selected cutaneous malignancies, following successful regulatory review of the IND.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top